MedTrace Logo

Early Detection of Epstein-Barr Virus Related Disease.

NCT03546101 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1527

Last updated 2023-10-31

No results posted yet for this study

Summary

Epstein-Barr virus (EBV) is one of several herpesviruses that cause disease in humans. EBV virus has an oncogenic potential, and it has been associated with the development of a wide range of cancers. Previous studies have shown a close association between EBV and Post-Transplant Lymphoproliferative disorder (PTLD) in transplant recipients. As part of a preventive approach against PTLD, several transplantation units now monitor the occurrence of EBV-DNAemia after transplantation. However, there is little evidence to guide this strategy; nor is there consensus concerning either the best specimen to use for EBV analysis (whole blood or plasma).

In this study investigators aim to optimise and validate a polymerase chain reaction (PCR)-test for EBV-DNA on, respectively, whole blood, plasma and a combination of plasma and lymphocytes.

The investigators wish to determine which of the three tests best predicts current and future risk of development of EBV-related diseases such as mononucleosis and PTLD.

Conditions

  • Post-transplant Lymphoproliferative Disorder
  • Mononucleosis
  • Epstein-Barr Virus Infections
  • Epstein-Barr Virus Related Malignancy
  • Epstein-Barr Viraemia
  • Epstein-Barr Virus-Related Hodgkin Lymphoma
  • Epstein-Barr Virus-Related Non-Hodgkin Lymphoma
  • Hemophagocytic Lymphohistiocytoses
  • Hemophagocytosis

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Lene Ugilt, MD · University of Aarhus

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2019-03-01
Completion
2023-05-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03546101 on ClinicalTrials.gov